HMGB1: A Potential Therapeutic Target for Non-Small Cell Lung Cancer
Anlin Feng
Affiliation
- 1Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China
- 2Department of Immunology, School of Basic Medical Sciences, Wuhan University, Wuhan, China
Corresponding Author
Zhenbo Tu, Department of Immunology, School of Basic Medical Sciences, Wuhan University, Donghu Road 185#, Wuchang, Wuhan 430071, China, E-mail: zhenbotu@whu.edu.cn
Citation
Tu, Z., et al. HMGB1: A Potential Therapeutic Target for Non-Small Cell Lung Cancer. (2016) Lett Health Biol Sci 1(2): 28- 29.
Copy rights
© 2016 Tu, Z. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
Keywords
Abstract
Recent studies have found HMGB1 as a potential and valuable bio-marker for NSCLC. Many targeted therapies have been developed with effective clinical proofs; however treatment responses are typically short-lived because of the frequent mutation of target genes. HMGB1 which has been targeted in several cancer therapies for its conservative feature would possess a potential clinical value for NSCLC treatment.
